|
Characteristics of the study cohort |
||
| No cancer detected n = 548 |
Diagnosed with cancer n = 192 |
|
|
|
||
| Clinical characteristics |
||
| Age at venipuncture (years) |
61 (58, 64) |
61 (58, 64) |
| Total PSA (ng/ml) |
4.21 (3.39, 5.55) |
5.81 (4.07, 10.4) |
| Free PSA (ng/ml) |
0.87 (0.66, 1.25) |
0.83 (0.60, 1.35) |
| Intact PSA (ng/ml) |
0.37 (0.28, 0.52) |
0.43 (0.29, 0.73) |
| Human kallikrein 2 (ng/ml) |
0.046 (0.030, 0.068) |
0.076 (0.050, 0.128) |
|
|
||
| Tumor characteristics |
||
| Abnormal DRE |
50 (9%) |
76 (40%) |
| Biopsy Gleason score |
||
| ≤6 |
152 (79%) |
|
| 7 |
33 (17%) |
|
| ≥8 |
7 (4%) |
|
|
Data are median (interquartile range) or frequency (percentage). DRE, digital rectal examination; PSA, prostate specific antigen. | ||
Vickers et al. BMC Medicine 2008 6:19 doi:10.1186/1741-7015-6-19 |
||